About F-star

Overview

F-star is a leader in the discovery and development of novel bispecific antibodies

F-star is a biopharmaceutical company focused on developing immuno-oncology bispecific antibody therapeutics.

We are poised to dominate the bispecific antibody space in immuno-oncology through the application of our highly efficient Modular Antibody Technology™ platform.

Our powerful platform enables the discovery of novel bispecific antibodies, which are selected for their potential to transform the treatment of cancer. 

IMG 3599

The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including: AbbVie, Bristol-Myers Squibb, Merck KGaA and Denali Therapeutics.

We have built a comprehensive IP estate around our technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.

F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors.

F-star currently employs over 80 people at its research site in Cambridge, UK.

 

Recognition

F-star is proud to have been recognised for the following awards:

WINNER OF

 
2017 Biotech and Money Awards - UK Life Science Deal of the Year
2017 Biotech and Money Awards - CEO of the Year
2017 Business Weekly Awards - Life Science Innovation of the Year
2011 Fierce 15
   

FINALIST OF

 
2017 Scrip Awards - Best Partnership Alliance
2017 Scrip Awards - Business Development team of the Year
2017 OBN Awards - Best Established Biotech
2017 OneNucleus - BioNewsRound Award
2017 Mediscience - The Emerging Star Award
2017 Business Excellence Awards  - Employer of the Year